Ameluz
Total Payments
$4.5M
Transactions
7,758
Doctors
3,023
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $245,535 | 20 | 5 |
| 2023 | $2.0M | 78 | 3 |
| 2022 | $723,223 | 58 | 8 |
| 2021 | $8,000 | 1 | 0 |
| 2020 | $5,500 | 2 | 1 |
| 2019 | $446,702 | 2,119 | 1,330 |
| 2018 | $911,786 | 2,949 | 1,552 |
| 2017 | $167,518 | 2,531 | 1,460 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.8M | 193 | 85.8% |
| Food and Beverage | $191,246 | 6,935 | 4.3% |
| Honoraria | $157,846 | 461 | 3.5% |
| Consulting Fee | $141,350 | 60 | 3.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $91,647 | 61 | 2.0% |
| Debt forgiveness | $37,248 | 2 | 0.8% |
| Travel and Lodging | $16,395 | 37 | 0.4% |
| Grant | $2,500 | 1 | 0.1% |
| Gift | $77.00 | 7 | 0.0% |
| Entertainment | $48.00 | 1 | 0.0% |
Payments by Type
Research
$3.8M
193 transactions
General
$638,357
7,565 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ALA-BCC-CT013 | Biofrontera Bioscience GmbH | $1.0M | 0 |
| ALA-AK-CT018 | Biofrontera Bioscience GmbH | $723,744 | 0 |
| A randomized, double blind, vehicle-co ntrolled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). | Biofrontera Inc. | $691,748 | 12 |
| ALA-ACV-CT014 | Biofrontera Bioscience GmbH | $580,503 | 0 |
| ALA-AK-CT019 | Biofrontera Bioscience GmbH | $359,026 | 0 |
| A Randomized, Double-Blind, Parallel Group Comparison Study to Determine teh safety and effiacy of Ameluz | Biofrontera Inc. | $129,290 | 1 |
| "Short contact protocols to reduce pain during actinic keratosis treatment with ALA gel red light photodynamic therapy (PDT)" | Biofrontera Inc. | $38,446 | 0 |
| Safety and Efficacy of Photodynamic Therapy with Aminolevulinic Acid 10% Topical Gel Activated by Red Light versus Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study | Biofrontera Inc. | $35,703 | 0 |
| Retrospective descriptive study on PDT with Ameluz 10% | Biofrontera Inc. | $31,000 | 1 |
| A Single Observational Study to Evaluate the Effectiveness and Safety of Cryotherapy in Combination with 10% ALA Gel Red Light PDT in the Treatment of Actinic Keratosis on the Full Face | Biofrontera Inc. | $28,305 | 0 |
| ALA-AK-CT019 | Biofrontera Inc. | $25,488 | 0 |
| AMELUZ PDT | Biofrontera Inc. | $24,975 | 0 |
| Photodynamic Therapy for Squamous Cell Carcinoma In Situ on the trunk and extremities with ALA 10% Gel and Red light Illumination | Biofrontera Inc. | $23,982 | 1 |
| Short contact protocols to reduce pain during actinic keratosis treatment with ALA gel red light photodynamic therapy (PDT) | Biofrontera Inc. | $20,473 | 0 |
| ALA-ACV-CT014 | Biofrontera Inc. | $14,746 | 0 |
| Photodynamic Therapy with Ameluz and BF-RhodoLED lamp With and Without Topical Adapelene Gel 0.1% Pre-Treatment in the Treatment of Dorsal Hand/Forearm Actinic Keratosis | Biofrontera Inc. | $11,425 | 1 |
| A Single Center, Retrospective, Observational, Descriptive Case Series on the Safety of Photodynamic Therapy with Ameluz (aminolevulinic acid hydrochloride) 10% Gel PDT for Adult Subjects with Actinic Keratosis | Biofrontera Inc. | $11,250 | 1 |
| Safety and Efficacy of Photodynamic Therapy with Aminolevulinic Acid 10% Topical Gel Activated by Red Light Versus Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study | Biofrontera Inc. | $11,000 | 0 |
| CTO14 | Biofrontera Inc. | $10,000 | 0 |
| Photodynamic Therapy for Squamous cell carcinoma in situ on the extremities with ALA 10% gel and red light illumination | Biofrontera Inc. | $9,026 | 1 |
Top Doctors Receiving Payments for Ameluz
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Diego, CA | $3.6M | 127 |
| , M.D | Dermatology | Aventura, FL | $132,141 | 6 |
| , MD | Dermatology | Phoenix, AZ | $61,493 | 38 |
| , MD, PA | Dermatology | Arlington, TX | $53,528 | 15 |
| , M.D | Anatomic Pathology & Clinical Pathology | Saginow, MI | $21,456 | 1 |
| , M.D | Dermatology | Norfolk, VA | $20,473 | 15 |
| , D.O | Dermatology | Kerrville, TX | $18,841 | 36 |
| , M.D | Dermatology | Charleston, SC | $17,106 | 19 |
| , M.D | Dermatology | Davenport, IA | $15,792 | 1 |
| , M.D | MOHS-Micrographic Surgery | Englewood, CO | $15,752 | 16 |
| , MD | MOHS-Micrographic Surgery | Sacramento, CA | $14,274 | 13 |
| , M.D | Dermatology | Smithtown, NY | $14,060 | 13 |
| , M.D | MOHS-Micrographic Surgery | West Des Moines, IA | $13,291 | 17 |
| , M.D | Dermatology | Miami, FL | $12,158 | 4 |
| , M.D | MOHS-Micrographic Surgery | Charlotte, NC | $12,105 | 10 |
| , M.D | MOHS-Micrographic Surgery | Ft Lauderdale, FL | $11,968 | 6 |
| , M.D | Procedural Dermatology | San Diego, CA | $10,669 | 11 |
| , MD PHD | Dermatology | New York, NY | $8,042 | 3 |
| , MD | MOHS-Micrographic Surgery | Carmel, IN | $7,631 | 15 |
| , M.D | Student in an Organized Health Care Education/Training Program | New York, NY | $7,048 | 11 |
| , M.D | Dermatology | Westchester, IL | $6,852 | 13 |
| , M.D | Dermatology | Bryn Mawr, PA | $5,748 | 14 |
| , MD | Dermatology | San Diego, CA | $5,606 | 12 |
| , DO | MOHS-Micrographic Surgery | Las Vegas, NV | $5,019 | 3 |
| , M.D., PH.D | Procedural Dermatology | Chicago, IL | $4,835 | 4 |
Ad
Manufacturing Companies
- Biofrontera Bioscience GmbH $2.7M
- Biofrontera Inc. $1.8M
Product Information
- Type Drug
- Total Payments $4.5M
- Total Doctors 3,023
- Transactions 7,758
About Ameluz
Ameluz is a drug associated with $4.5M in payments to 3,023 healthcare providers, recorded across 7,758 transactions in the CMS Open Payments database. The primary manufacturer is Biofrontera Bioscience GmbH.
Payment data is available from 2017 to 2024. In 2024, $245,535 was paid across 20 transactions to 5 doctors.
The most common payment nature for Ameluz is "Unspecified" ($3.8M, 85.8% of total).
Ameluz is associated with 20 research studies, including "ALA-BCC-CT013" ($1.0M).